549. Monoclonal Antibody Therapy for COVID-19 Infection in Michigan: The Flint Experience

BACKGROUND: Bamlanivimab (BAM), a neutralizing IgG1 monoclonal antibody (mAb), received emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for treatment of mild to moderate COVID-19 infection in patients 12 years of age and older weighing at least 40 kg at high risk for...

Descripción completa

Detalles Bibliográficos
Autores principales: Younas, Mariam, Osterholzer, Danielle, Flues, Brandon R, Rios-Bedoya, Carlos, McDonald, Philip, Bachuwa, Ghassan, Tupper, Michael W, Jaggi, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690772/
http://dx.doi.org/10.1093/ofid/ofab466.748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690772/
http://dx.doi.org/10.1093/ofid/ofab466.748

Ejemplares similares